Platinum chromium coronary stent with enhanced delivery system now available in Canada
NATICK, Mass., April 25, 2012 /CNW/ - Boston Scientific Corporation (NYSE: BSX) announces Health Canada approval and market launch of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in Canada. The first patient implant in Canada using the new device was recently performed by Philippe L'Allier, M.D., Cath Lab Director at the Montreal Heart Institute. The new stent system incorporates the platinum chromium (PtCr) alloy and innovative stent design of the PROMUS Element Stent with an enhanced catheter delivery system engineered for improved performance in treating patients with coronary artery disease. The Company plans to begin marketing the product immediately in Canada.
"The unique PtCr alloy and stent architecture of the PROMUS Element Stent offer significant advantages in conformability, radial strength and visibility compared to other stent platforms," said Dr. L'Allier. "The best-in-class deliverability of the PROMUS Element Plus Stent System will help in accessing challenging lesions."
The PROMUS Element Stent, part of the PROMUS Element Stent System and the PROMUS Element Plus Stent System, uses a proprietary PtCr alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, excellent conformability and higher radial strength. The PROMUS Element Plus Stent System employs an advanced low-profile delivery system featuring a dual-layer balloon designed to enable precise stent delivery across challenging lesions and reduce balloon growth during inflation to facilitate high-pressure stent deployment. The everolimus drug and fluorinated copolymer used on the PROMUS Element Stent have been studied in multiple randomized clinical trials and 'real-world' registries, demonstrating excellent long-term safety and efficacy.
"We are pleased to introduce the PROMUS Element Plus Stent System to physicians and patients in Canada," said Kevin Ballinger, President of the Interventional Cardiology Division at Boston Scientific. "This advanced stent is supported by strong clinical outcomes from the PLATINUM trial, which demonstrated very low rates of revascularization and stent thrombosis at one and two years. It is the latest example of Boston Scientific's commitment to market leadership and continued innovation in drug-eluting stents."
In the U.S., the PROMUS Element Plus Stent System was approved by the Food and Drug Administration in 2011.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, new product launches and launch cadence, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Boston Scientific Corporation
For further information: